This study investigated knowledge, attitude and
practice toward premarital/prenatal genetic testing among young people of
15-45years of age in Sapele Local Government Area in Delta State Nigeria.
Descriptive survey research design was used. The population of the study
consisted of the members of four major communities (Amukpe, Amuogoddo, Okirighwe
and Uguanja). The respondents were selected by simple random sampling method.
The research instrument was a self-constructed questionnaire. A total of 50
respondents were selected. A total 50 questionnaire were distributed and same
retrieved. The objectives of the study were to determine level of knowledge of
premarital/prenatal genetic testing among young people, to assess the level of
practice and to identify factors influencing their attitude towards
premarital/prenatal genetic testing. The rational is to enhance young people’s
knowledge about premarital/prenatal genetic testing, encourage
premarital/prenatal genetic screening and also reduces some of the factors
influencing attitudes of young people towards premarital/prenatal genetic
testing. Data collected were analyzed using frequency and percentages and were
presented using tables and graphs. The study shows that 30% of the respondent
level of knowledge of premarital/premarital genetic testing is of high level,
70% of the respondents have low level of knowledge and the source of
information was through media (20%), health personnel (40%), friends (6%) etc.
The study also showed that the level of practice is low as 80% of the
respondent does not practice premarital/prenatal genetic testing, only 20%
practiced it. it also shows that there are some factors influencing their
attitudes towards premarital/prenatal genetic testing which include lack of
knowledge (66%), non affordability (20%), non Accessibility (55) and also as a
result of non availabilities of centers (15%) where premarital/prenatal genetic
testing should be carried out. In conclusion, lack of basic knowledge, negative
attitude and practice has a negative impact on the young people, their family, their
community and the society as a whole. It is therefore recommended that effort
should be made by government, parents, and health personnel to improve
knowledge, attitude and practice towards premarital/prenatal genetic testing
thereby reducing the incidence rate of having children with genetic defect.
Lippman (2001): The View from de Womb, Genetics: Ethics to Order Remain a
Pipedream. Newsletter. 8 November 2003. p.64.
D. N., Hopmann, M. R., Barsel-Bowers, G. & Goldstein, A. (2001). Anxiety in
Women with Low Maternal Serum Alpha-Fetoprotein Screening Results. Prenatal
Diagnosis. 11, 381-385.
P., & Colton, T. (eds.) (2008). Encyclopedia of Biostatistics Volume 5.
Boston: John Wiley & Sons.
A.L (2002): Prevention of the first Occurrence of Neural Tube Defects by
Periconceptual Vitamin Supplementation. The New England Journal of Medicine,
R, Ozgur. D., Oz. U. Tan,
A. Hunter. D. Copel, J., & Mahoney, M. J.
(2008). An Alternative for Women initially Declining Genetic Amniocentesis:
Individual Down Syndrome Odds on the basis of Maternal Age and Multiple Ltitrasonographic
Markers. American Journal of Obstetrics and Gyhecology. 179: 5 14-9.
J. & Golbus, 0 (2009): Who’s for Amniocentesis? The Politics of Prenatal
Screening. In H. Homans (ed,) The Sexual Politics of Reproduction. London:
Gower. (pp. 96-177).
M. H., Pandian. M. R. Jones O. W. (2007). Abnormal Maternal Serum Chorionic
Gconadotrophin: Levels in Pregnancies with fetal Chromosome Abnormalities.
Prenatal Diagnosis. 7, 1 97-200.
B.K (2012): Elevated Maternal Serum Alpha-Fetoprotein (MSAFP): Interpretation
and Follow-up. In R. M. Pitkin. Jr. & J. R. Scott (eds), Clinical
Obstetrics and Gynecology. 31. 293-205.
J.H (2011) Screening of Maternal Serum for Fetal Down’s Syndrome in the First
Trimester. New England Journal of Medicine, 338, 955-961.
R. T. (2005). Introduction. In R.T. Croyle (ed). Psychosocial Effects of
Screening for Disease Prevention and Detection. (pp. 3-7).
H (2011) Combining Inhibin A with Existing Second-Trimester Markers in Maternal
Serum Screening for Down’s Syndrome. Prenatal Diagnosis, 16: 1095-1 100.
(2008) Psychosocial Aspects of Prenatal Screening and Diagnosis. In T. Marteau
and M. Richards (eds) The Troubled Helix: Social and Psychological Implications
Of The New Human Genetics. New York: Cambridge. (pp.140-163).
J. M., (2013). Scientific Criteria for adopting Health Screening Measures.
Pediatric Nursing. May/June. 195-197.
M. T. (2011), Knowledge and practice of prenatal genetic testing among married
MI. Bottoms. S.F., Carlucci. T. Grant, J., Belsky. R. L., Solyom, A. E., Quigg,
M. H., & Laferla. J. (200). Determinants of Altered Anxiety after Abnormal
Maternal Serum Fetoprotein Screening. American Journal of Obstetrics and
Gynecology. 159: 1501-4.
R. A. (2010). Obstetrical Sonoaraphy: The Best way to Terrif, a Pregnant Woman.
Journal of Ultrasound in Medicine, 19. 1-5.
J., Streets, K. & Priest. J. (2012). Maternal Serum Screening Risk for Down
Syndrome is Considered Positive if a Triple-Maker-Derived Risk Exceeds the
Age-Specific Risk: Use of this Definition for Women Aged 35 and over. Prenatal
Diagnosis. 13,2. 152-153.
B. (2003) Low Second Trimester Maternal Serum Unconjugated Oestriol in
Pregnancies with Down syndrome. British Journal of Obstetrics and Gynecology,
on the Line (2007), http://www.tav.sachs.org/taysachs.php.
on the Line (http://www.geiieticailiance.org)
on the Line (http://ww.dines.com.Retrived
on the Line (http://ww.encyclpedia.com.
on the Line (www.Google.com, retrieved
14th October 2012).
Unit, Department of Obstetrics and Gynecology. Centro de Education Medical
Investigations Clinics CEMIC, Institutor Universities IUC. Buenos Aires,
J.M. (2000). Prenatal Screening and Diagnosis: Some Psychological and Social
1ssue. British Journal of Obstetris and Gynecolohy, 97. 1074-(70).
(2011): Congenital Anterior Abdominal wall Defects in the North of England,
2006-2006: Occurrence and Outcome. Prenatal Diagnosis, 19(7): 662-8.
Botkin (2000) Medical Progress. Congenital Malformations: Etiologic factors and
their Role in Prevention. Part I. New England Journal of Medicine. 308 (8):
Marx (2009) Medical Progress. Congenital Malformations: Etiologic factors and
their Role in Prevention. Part II. New England Journal of Medicine. 308(9):
D., Basso V., Goldkrand P. & Butler S. 2001): The Genetic Screening of
Target Populations. In Backdoor to Eugenics. New York: Routledge.
E. Virginia; Kozma, Chahila: Weiss, Joan 0. Genetic Discrimination.
Perspectives of Consumers Science Vol 274. 24, Oct 2006. pp. 621-624.
D. M., & Mennuti, M.T.(2006). Neural Tube Defects: Issues in Prenatal
Diagnosis and Counseling. Obstetrics and Gynecology, 67, 1-16.
A (2003). Prenatal Detection and Diagnosis. in Clinical Genetics in Nursing
Practice. (pp. 271-293’). New York: Springer Publishing Company.
T. M. (2009). Psychological Costs of Screening. British Medical Journal, 299,
T.M., Johnston, M. Kidd J., Michie, S. Cook. R Slack J. & Shw, RV. (2002).
Psychological Models in Predicting Uptake of Prenatal Screening. Psychology and
Health. 6, 1 3-22.
G. E. (2006). Collaborative Study of Down Syndrome Screening using Maternal
Serum Alpha-Fetoprotein and Maternal Age. The Lancet, December 10-27. 1460.
G. E., Williams, J. & Haddow. J. E.(2009). New England Regional Genetics
Group Prenatal Collaborative Study of Down Syndrome Screening: Combining
Maternal Serum Alpha-Fetoprotein Measurements and Age to Screen for Down
Syndrome in Pregnant Women Under Age 35. American Journal of Obstetrics and
Gynecology, 160; 578-581.
and Zinn (2006) Psychological Consequences for Parents of False Negative
Results on Prenatal Screening for Down’s syndrome: Retrospective interview
Study. British Medical Journal, 320: 407-412.
Dillon, E., & Wright, L. (2009). Prenatal Diagnosis in the 2000s. Journal
of Obstetric, Gynecologic and Neonatal Nursing, 23; 506-5 15.
D. (2006): Alpha-Fetoprotein in the Antenatal Diagnosis of Anencephaly and
Spina Bifida. Lancet 2. 770, 197-200.
G (2004). Sensitivity arid specificity of Ultrasound for the Detection of
Neural Tube and Ventral Wall Defects Population. Obstetrics and Gynecology, 4.
O. (2006). Fetal Nuchal Translucency: Ultrasound Screening for Chromosomal
Defects in the First Trimester of Pregnancy. British Medical Journal, 304,
P and Cox D. (2008): Prenatal Screening for Down Syndrome with the use of
Maternal Serum Markers. New England Journal of Medicine, 327, 588-593.